flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 VisualAbstract: Improves in Patients with Type 2 Diabetes and Chronic Disease Kidney and Survival Benefits of

These findings led to a new wave of research and regulatory approvals focused specifically on obesity treatment, a condition affecting more than 650 million adults globally

Ozempic and Wegovy (semaglutide) target one receptor, GLP-1

Dec 10 2015;528(7581):262-266

doi: 10.1016/S0140-6736(18)32261-X 37 HomePDShamannaPStewartMYangFMillerMPerryCet al

A typical timeline looks like this: Results are often best when peptide therapy is combined with healthy nutrition and regular physical activity

Alli generally has fewer systemic side effects since it works locally in the gut, but can cause gastrointestinal issues like oily stools